Back to Search
Start Over
Combination of romidepsin with cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated patients with peripheral T-cell lymphoma: a non-randomised, phase 1b/2 study
- Source :
- The Lancet Haematology; April 2015, Vol. 2 Issue: 4 pe160-e165, 6p
- Publication Year :
- 2015
-
Abstract
- Romidepsin is a histone deacetylase inhibitor approved in the USA for patients with recurrent or refractory peripheral T-cell lymphoma and has shown activity in this setting with mainly haematological and gastrointestinal toxicity. Although it has limited efficacy, cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) therapy is widely used for treatment of de-novo peripheral T-cell lymphoma. We aimed to assess the safety, tolerability, and activity of romidepsin combined with CHOP in patients with previously untreated disease.
Details
- Language :
- English
- ISSN :
- 23523026
- Volume :
- 2
- Issue :
- 4
- Database :
- Supplemental Index
- Journal :
- The Lancet Haematology
- Publication Type :
- Periodical
- Accession number :
- ejs35403128
- Full Text :
- https://doi.org/10.1016/S2352-3026(15)00023-X